Cantor Fitzgerald Has Weak Outlook for UTHR FY2025 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of United Therapeutics in a note issued to investors on Thursday, October 30th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings per share of $27.64 for the year, down from their previous estimate of $28.70. Cantor Fitzgerald currently has a “Overweight” rating and a $525.00 target price on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Cantor Fitzgerald also issued estimates for United Therapeutics’ FY2026 earnings at $28.42 EPS.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $501.90.

United Therapeutics Stock Down 1.8%

Shares of UTHR opened at $445.43 on Monday. The company has a 50-day simple moving average of $410.07 and a 200-day simple moving average of $338.73. The company has a market capitalization of $19.18 billion, a PE ratio of 16.88, a P/E/G ratio of 4.96 and a beta of 0.66. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $479.50.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the business earned $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $450.34, for a total transaction of $4,953,740.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $16,563,955.54. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of the business’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $448.96, for a total transaction of $1,795,840.00. Following the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $58,364.80. This trade represents a 96.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 368,435 shares of company stock worth $152,863,012 over the last 90 days. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Principal Financial Group Inc. lifted its holdings in United Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 111,861 shares of the biotechnology company’s stock worth $34,483,000 after purchasing an additional 309 shares during the period. GF Fund Management CO. LTD. raised its holdings in United Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,143 shares of the biotechnology company’s stock worth $352,000 after buying an additional 206 shares during the period. IFM Investors Pty Ltd increased its holdings in shares of United Therapeutics by 5.9% in the 1st quarter. IFM Investors Pty Ltd now owns 8,682 shares of the biotechnology company’s stock valued at $2,676,000 after purchasing an additional 484 shares during the period. Brookstone Capital Management acquired a new position in shares of United Therapeutics in the 1st quarter valued at about $1,479,000. Finally, World Investment Advisors increased its holdings in shares of United Therapeutics by 79.2% in the 1st quarter. World Investment Advisors now owns 2,328 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 1,029 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.